365 related articles for article (PubMed ID: 34026476)
1. Viral inhibitors derived from macroalgae, microalgae, and cyanobacteria: A review of antiviral potential throughout pathogenesis.
Reynolds D; Huesemann M; Edmundson S; Sims A; Hurst B; Cady S; Beirne N; Freeman J; Berger A; Gao S
Algal Res; 2021 Jul; 57():102331. PubMed ID: 34026476
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
[TBL] [Abstract][Full Text] [Related]
4. Plant-Derived Epi-Nutraceuticals as Potential Broad-Spectrum Anti-Viral Agents.
Gabbianelli R; Shahar E; de Simone G; Rucci C; Bordoni L; Feliziani G; Zhao F; Ferrati M; Maggi F; Spinozzi E; Mahajna J
Nutrients; 2023 Nov; 15(22):. PubMed ID: 38004113
[TBL] [Abstract][Full Text] [Related]
5. Cyanobacteria and Algae-Derived Bioactive Metabolites as Antiviral Agents: Evidence, Mode of Action, and Scope for Further Expansion; A Comprehensive Review in Light of the SARS-CoV-2 Outbreak.
Pradhan B; Nayak R; Patra S; Bhuyan PP; Dash SR; Ki JS; Adhikary SP; Ragusa A; Jena M
Antioxidants (Basel); 2022 Feb; 11(2):. PubMed ID: 35204236
[TBL] [Abstract][Full Text] [Related]
6. Molecular scaffolds from mother nature as possible lead compounds in drug design and discovery against coronaviruses: A landscape analysis of published literature and molecular docking studies.
Khursheed A; Jain V; Rasool A; Rather MA; Malik NA; Shalla AH
Microb Pathog; 2021 Aug; 157():104933. PubMed ID: 33984466
[TBL] [Abstract][Full Text] [Related]
7. Structural Basis for the Understanding of Entry Inhibitors against SARS Viruses.
Kushwaha PK; Kumari N; Nayak S; Kishor K; Sharon A
Curr Med Chem; 2022; 29(4):666-681. PubMed ID: 33992054
[TBL] [Abstract][Full Text] [Related]
8. The Potential of Algal Biotechnology to Produce Antiviral Compounds and Biopharmaceuticals.
Rosales-Mendoza S; García-Silva I; González-Ortega O; Sandoval-Vargas JM; Malla A; Vimolmangkang S
Molecules; 2020 Sep; 25(18):. PubMed ID: 32899754
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic potential of green tea catechin, (-)-epigallocatechin-3-
Dinda B; Dinda S; Dinda M
Phytomed Plus; 2023 Feb; 3(1):100402. PubMed ID: 36597465
[TBL] [Abstract][Full Text] [Related]
10. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
11. Japan-China Joint Medical Workshop on Drug Discoveries and Therapeutics 2008: The need of Asian pharmaceutical researchers' cooperation.
Nakata M; Tang W
Drug Discov Ther; 2008 Oct; 2(5):262-3. PubMed ID: 22504718
[TBL] [Abstract][Full Text] [Related]
12. Emergence and Re-emergence of Human Coronaviruses: Spike Protein as the Potential Molecular Switch and Pharmaceutical Target.
Ahmad F; Kamal MA; Tekwani BL
Curr Pharm Des; 2021; 27(33):3566-3576. PubMed ID: 33327904
[TBL] [Abstract][Full Text] [Related]
13. Multi-omics insights into host-viral response and pathogenesis in Crimean-Congo hemorrhagic fever viruses for novel therapeutic target.
Neogi U; Elaldi N; Appelberg S; Ambikan A; Kennedy E; Dowall S; Bagci BK; Gupta S; Rodriguez JE; Svensson-Akusjärvi S; Monteil V; Vegvari A; Benfeitas R; Banerjea A; Weber F; Hewson R; Mirazimi A
Elife; 2022 Apr; 11():. PubMed ID: 35437144
[TBL] [Abstract][Full Text] [Related]
14. Targeting the Fusion Process of SARS-CoV-2 Infection by Small Molecule Inhibitors.
Park SB; Irvin P; Hu Z; Khan M; Hu X; Zeng Q; Chen C; Xu M; Leek M; Zang R; Case JB; Zheng W; Ding S; Liang TJ
mBio; 2022 Feb; 13(1):e0323821. PubMed ID: 35012356
[TBL] [Abstract][Full Text] [Related]
15. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
16. Involvement of epigenetics in affecting host immunity during SARS-CoV-2 infection.
Behura A; Naik L; Patel S; Das M; Kumar A; Mishra A; Nayak DK; Manna D; Mishra A; Dhiman R
Biochim Biophys Acta Mol Basis Dis; 2023 Mar; 1869(3):166634. PubMed ID: 36577469
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial peptides: A promising tool to combat multidrug resistance in SARS CoV2 era.
Saini J; Kaur P; Malik N; Lakhawat SS; Sharma PK
Microbiol Res; 2022 Dec; 265():127206. PubMed ID: 36162150
[TBL] [Abstract][Full Text] [Related]
18. Antiviral plant-derived natural products to combat RNA viruses: Targets throughout the viral life cycle.
Owen L; Laird K; Shivkumar M
Lett Appl Microbiol; 2022 Sep; 75(3):476-499. PubMed ID: 34953146
[TBL] [Abstract][Full Text] [Related]
19. Marine Algal Antioxidants as Potential Vectors for Controlling Viral Diseases.
Sansone C; Brunet C; Noonan DM; Albini A
Antioxidants (Basel); 2020 May; 9(5):. PubMed ID: 32392759
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
